Search results
Showing 1 to 10 of 10 results for ivabradine
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
This quality standard covers diagnosing and managing stable angina in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS21Show all sections
Sections for QS21
- Quality statements
- Quality statement 1: Diagnostic investigation
- Quality statement 2: First-line treatment
- Quality statement 3: Medical treatment before revascularisation
- Quality statement 4: Multidisciplinary team
- Quality statement 5: Symptoms not responding to treatment
- Update information
- About this quality standard
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
and cost effectiveness of adding a newer anti-anginal drug (nicorandil, ivabradine or ranolazine) to a calcium channel blocker for...
Optimising Medication in patients with Chronic Heart Failure
Ivabradine for treating chronic heart failure
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information
and cost effectiveness of adding a newer anti-anginal drug (nicorandil, ivabradine or ranolazine) to a calcium channel blocker for...